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The incidence of prostate cancer varies worldwide, with the highest 
rates reported in the USA, and the lowest in parts of Asia. Prostate 
cancer incidence rates are 1.6 - 1.9 times higher, and mortality rates 
2 - 3 times higher, among African-American men (AAM) than 
Caucasian-American men (CAM).1-6 AAM are younger at diagnosis, 
have higher grade and stage tumours and a worse prognosis, which 
may be due to greater biological aggressiveness.5,7,8
South Africa’s population diversity offers an opportunity to compare 
disease patterns among different racial or ethnic groups living in the 
same geographical area. The population of Western Cape Province 
comprises white immigrants from Europe, blacks originally from 
central Africa, and coloureds, which refers to the group descended 
predominantly from indigenous Khoi and San inhabitants, with 
genetic input from subsequent European and Asian immigrants.9,10
Earlier studies suggested that prostate cancer was rare among 
indigenous blacks compared with whites living in Africa.11 However, 
the low incidence rates reported in African countries may be due to 
under-diagnosis and under-reporting, as a result of poorer access to 
screening and diagnostic facilities, or lack of national cancer registries. 
Some African countries have high incidence rates of prostate cancer, 
probably attributable to improved prostate-specific antigen (PSA) 
testing and diagnostic facilities and increased life expectancy.7,9
Because of the extensive literature on racial differences in prostate 
cancer among men in the USA and the lack of such studies in African 
countries, we aimed to compare the presenting features and management 
of prostate cancer in men of different race in the Western Cape.
Patients and methods
We analysed the data on all men with a diagnosis of prostate cancer 
seen at the Urological Oncology Clinic of Tygerberg Hospital (a 
tertiary level public sector hospital) from January 1995 to December 
2005. Most patients were referred from primary health care facilities 
in Western Cape Province (where PSA screening of asymptomatic 
men is not readily available) and almost all presented because of 
prostate cancer-related symptoms.
The patient’s race was self-assigned as white, coloured or black. 
The cancers were clinically staged according to the 2002 TNM 
classification. Clinical tumour stage was determined by digital rectal 
examination (DRE) as T1 = (clinically benign), T2 = palpable cancer 
confined to the prostate, T3 = invasion of the prostatic capsule, or T4 
= involvement of peri-prostatic tissues. Haematogenous metastases 
were detected by radiography or skeletal scintigraphy.
The diagnosis of prostate cancer was confirmed by histological 
examination of specimens obtained by transrectal biopsy or 
transurethral resection of the prostate (TURP). Indications for 
prostate biopsy included a serum PSA >4 ng/ml or a suspicious DRE. 
A clinical diagnosis (without histological confirmation) was made in 
some patients, based on clinical stage T3/4 prostate cancer on DRE, 
serum PSA >50 ng/ml, or sclerotic bone metastases on pelvic and 
vertebral X-rays.12 Histological grading was performed according to 
the MD Anderson system, which distinguishes between grades 1, 2 
and 3: well, moderately and poorly differentiated.
Treatment decisions were taken at a weekly urology/oncology 
meeting where treatment options were discussed with the patient 
and his family. The final decision about treatment was taken by the 
patient in consultation with his family.Corresponding author: C Heyns (cfh2@sun.ac.za)
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Objectives. We aimed to compare the presenting features and 
management of prostate cancer among different racial groups.
Patients and methods. We studied all patients diagnosed with 
prostate cancer at the Urological Oncology Clinic, Tygerberg 
Hospital, from January 1995 to December 2005. Most presented 
symptomatically as PSA screening is not readily available in 
the referral area of the hospital. Race was self-defined as white, 
coloured or black. Statistical analysis was performed using Student’s 
t-test or Fisher’s exact test, where appropriate. A two-tailed p-value 
<0.05 was accepted as statistically significant.
Results. There were 901 patients: 291 (32.3%) white, 539 (59.8%) 
coloured and 71 (7.9%) black. Mean age at presentation was 
significantly higher in the white than the coloured and black groups 
(69.7, 67.9 and 68.9 years, respectively). Grade 1 adenocarcinoma 
was most common in the white (37%) and coloured groups (38%), 
and grade 2 was most common in the black group (39%). There 
was a significantly lower percentage of patients with T3-4 disease 
at diagnosis in the white group (47%) than the coloured (61%) and 
black (62%) groups. Mean serum PSA at diagnosis was significantly 
higher in the black than the coloured and white groups (766.1, 673.3 
and 196.1 ng/ml, respectively). Potentially curative therapy (radical 
prostatectomy or radiotherapy) was chosen by 31% of white, 23% 
of coloured and only 12% of black patients. The mean duration of 
follow-up was significantly shorter in the black than in the white or 
coloured groups (24.0, 31.5 and 35.0 months, respectively).
Conclusions. Black men presented with higher grade and stage 
disease and higher serum PSA, received potentially curative 
treatment less often, and had a shorter follow-up (probably owing 
to shorter survival) than the white and coloured groups. Greater 
prostate cancer awareness and education among patients and 
physicians and more widespread use of PSA screening of pre-
symptomatic men at risk of prostate cancer is needed.
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Relevant details in the clinical records were prospectively entered 
by a single data capturer on an Excel database. These were analysed in 
2009, allowing a minimum potential follow-up of 3 years for patients 
seen up to December 2005. Statistical analysis was performed using 
GraphPad Instat software. Comparison of means was performed 
using Student’s t-test for parametric data and the Mann-Whitney test 
for non-parametric data. Fisher’s exact test was used for contingency 
table analysis. A two-tailed p-value <0.05 was accepted as statistically 
significant.
Results
The study included 901 patients: 291 (32.3%) white, 539 (59.8%) 
coloured and 71 (7.9%) black, which reflects the demography of 
patients seen at Tygerberg Hospital.
Mean age at presentation was significantly higher in the white 
than the coloured and black groups (69.7, 67.9 and 68.9 years, 
respectively). The peak age incidence was 80 - 89 years in the white 
group, and 70 - 79 years in the coloured and black groups (Fig. 1).
Among patients where the histological grading was available, grade 
1 was the most common grade in the white (37%) and coloured groups 
(38%), and grade 2 the most common in the black group (39%) (Fig. 2).
The most common clinical tumour stage at presentation was T1-2 
in white patients (53%) and T3-4 in the coloured (61%) and black 
groups (62%) (Fig. 3).
In patients with known M-stage, metastatic disease was most 
common in the black (53%) and least common in the white group 
(28%) (Fig. 4).
Mean and median serum PSA values at presentation were 
significantly higher in the black and coloured than the white group. 
There was a marked difference between the mean and median PSA 
values in all three groups, owing to a few extremely high outlier PSA 
values (Table I). Mean serum PSA was significantly increased in 
higher grade and higher stage cancer (Table I).
Over half of the patients, irrespective of race, received androgen 
deprivation therapy (ADT) as first-line treatment (Fig. 5). Watchful 
waiting (WW) was the second most common management choice in 
black patients. Potentially curative therapy was given in 31% of white, 
23% of coloured and only 12% of black patients (Fig. 5).
Among men aged <70 years with clinically localised cancer (T1-2 
M0) in whom potentially curative therapy is indicated, radical 

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Fig. 2. Histological grade at presentation (1 = well, 2 = moderately, 3 = poor-
ly differentiated).
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Fig. 3. Tumour stage at presentation.
Fig. 1. Age distribution according to race.
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Fig. 4. Metastases (M-stage) at presentation.
Fig. 5. Initial treatment.
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prostatectomy (RP) was chosen by 31.9%, 42.5% and 15% of white, 
coloured and black patients, respectively, whereas radiotherapy (RT) 
was chosen by 31.9%, 20.6% and 15% of the same groups, respectively. 
The remainder opted for WW or ADT.
In men aged >70 years with locally advanced or metastatic 
cancer (T3-4 or M1) in whom only palliative or deferred treatment 
is indicated, ADT was used in 66.7%, 85% and 86.3%, and WW 
was chosen by 17.4%, 8.2% and 9.8% of white, coloured and black 
patients, respectively.
Patients were most often lost to follow-up with no reason available, 
and were known to have died in 11% of the white and coloured 
groups, and in only 1.4% of the black group. The mean duration of 
follow-up was significantly shorter in the black than in the white or 
coloured groups, and it was also shorter in high-grade than low-grade 
cancer, and in higher clinical stage compared with lower stage cancer 
(Table II).
Discussion
In the USA, the average age of AAM at presentation with prostate 
cancer is approximately 3 years younger than that of CAM.3 The 
peak age at diagnosis of prostate cancer in African countries is on 
average a decade earlier than in developed countries.9 However, 
Senegalese men diagnosed with prostate cancer had a significantly 
higher mean age than AAM in the USA (69 v. 61 years). The probable 
explanation is that most men in the USA were diagnosed earlier by 
PSA screening, whereas Senegalese men were most often diagnosed 
later with prostate cancer-related symptoms.4
In the present study, the mean age of the coloured and black groups 
was slightly but significantly lower than that of the white group, and 
the peak age at presentation was a decade earlier (Fig. 1). The peak 
age at presentation depends on life expectancy of the population, 
which is considerably lower in most African countries than in the 
USA. The incidence of prostate cancer increases progressively with 
age; therefore, in a population with a longer life expectancy and 
greater numbers of older men, there will be a greater proportion of 
older men with prostate cancer.
Studies have suggested that AAM in the USA present with higher 
grade and more aggressive prostate cancer.14 In Nigerian men with 
adenocarcinoma of the prostate, 50% had G3 tumours, which 
accounted for 82% of paraplegics and 52% of deaths occurring within 
12 months.11
In our study, grade 1 was most common in white and coloured 
patients, while grades 2 and 3 were more common in black men 
(Fig. 2), which may indicate that black men have biologically more 
aggressive prostate cancer, but may also be a selection artefact as 
black men with poorly differentiated cancer are more likely to present 
with clinical symptoms, whereas those with well differentiated cancer 
may remain undiagnosed.
Most studies in the USA have shown that AAM present with more 
advanced stages of prostate cancer compared with CAM, which is 
attributed to racial differences in socio-economic status, education 
level and the availability or use of healthcare services.3 A smaller 
proportion of AAM than CAM take part in voluntary screening 
programmes and undergo recommended prostate biopsies, especially 
in lower-income areas. Similarly in South Africa, a lower proportion 
of black than white men underwent a recommended prostate 
biopsy.14
In African countries, PSA testing and prostate biopsy are not 
readily available, therefore the diagnosis is usually made clinically in 
patients presenting with symptoms, or histologically after surgery for 
suspected benign prostatic hyperplasia (BPH).3,9,11 Most black men 
Table I. Serum PSA (ng/ml) at presentation according to 
race, histological grade and clinical stage
                                   Race
All White Coloured Black
Mean 526.3 196.1* 673.3*† 766.1*†
Median 33.5 19.6 42.5 105
Minimum 0.6 1 0.6 0.7
Maximum 36 213 6 000 36 213 19 120
                                   Grade
1 2 3 Unknown
Mean 206.8*† 407.3*† 802.2* 769.7†
Median 13.0 31.3 124.5 50.2
Minimum 0.6 1.0 1.0 0.7
Maximum 19 120 9 600 22 600 36 213
                                   Stage
T1 T2 T3 T4
Mean 16.0* 59.0* 226.1* 1 269.2*
Median 9.0 12.2 52.0 242.0
Minimum 0.6 1.0 1.0 2.0
Maximum 218 4 349 6 000 36 213
                                   Stage
N0 N+ M0 M+
Mean 99.9* 1 750.5* 93.7† 1 689.8†
Median 12.3 276.0 19.0 319.0
Minimum 6.0 6.1 1.0 3.0
Maximum 2 802 12 080 6 600 36 213
* and † denote values which are significantly different from other values in the same 
category marked with the same symbol (p<0.05).
Table II. Duration of follow-up (months) according to race, 
histological grade and clinical stage
All White Coloured Black
Mean 32.1 35.0* 31.5† 24.0*†
Median 21.0 24.0 21.0 14.0
Minimum 1.0 1.0 1.0 1.0
Maximum 173 169 173 101
G1 G3 T1 T2
Mean 43.4* 36.5* 34.9† 39.0
Median 35.0 27.0 26.5 27.0
Minimum 1.0 1.0 1.0 1.0
Maximum 169 173 141 152
T3 T4 M0 M1
Mean 35.4 24.8† 47.4‡ 24.4‡
Median 25.0 18.0 42.5 18.0
Minimum 1.0 1.0 1.0 1.0
Maximum 169 173 173 137
*, † and ‡ denote values which are significantly different from other values in the same 
category marked with the same symbol (p<0.05).
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in Africa present with locally advanced (41% - 96%) or metastatic 
disease (16% - 59%). Blacks outside Africa (e.g. in Jamaica) present 
with more advanced disease.4,11
In our study, locally advanced and metastatic disease was 
significantly more common in black and coloured than in white 
men (Figs 3 and 4). As in the USA, this fact may be attributed to 
racial differences in socio-economic status, education level and the 
availability or use of healthcare services.3
Studies have reported higher mean serum PSA at presentation in 
AAM than in CAM even after controlling for tumour stage.6 Elevated 
PSA at diagnosis could reflect late diagnosis owing to decreased 
access to healthcare or that the disease is more aggressive in AAM. 
Due to improved awareness and prostate cancer screening, the racial 
disparities in PSA appear to be decreasing in the USA.5
In our study, mean serum PSA was significantly higher in the black 
and coloured than in the white groups. A marked difference between 
the mean and median PSA values was due to a small number of very 
high outlier values which skewed the mean values. Therefore, median 
values should preferably be used to compare different groups.3,9 Mean 
serum PSA increased significantly according to the histological grade 
and clinical stage of prostate cancer. Therefore, the higher mean PSA 
in the black and coloured groups is explained by the higher grade and 
stage of prostate cancer in these groups.
AAM tend to receive potentially curative therapy less often, 
go untreated more often, are less likely to undergo RP, and more 
likely to receive RT or ADT than CAM.3,5,15 Reasons why black 
men are more likely to remain untreated include the desire to avoid 
treatment side-effects, fear, distrust of the health system, reliance on 
traditional healers, religious beliefs, differences in recommendations 
or preferences of physicians, advice from family and friends, or other 
information sources.5
In our study, potentially curative treatment was less often chosen 
by black than by coloured and white patients. Among men in whom 
potentially curative treatment was indicated, this was chosen by only 
a third of black men, compared with two-thirds of white and coloured 
men. Studies from the USA have suggested that there are no racial 
differences in mortality when there is equal treatment, suggesting 
that racial differences in patterns of care contribute to the racial 
disparity in survival.3
In our study, the mean duration of follow-up was significantly 
shorter in the black than in the white or coloured groups. Follow-up 
was also significantly shorter in high-grade than low-grade cancer, 
and in higher clinical stage than lower stage cancer. The most 
probable reason for loss to follow-up was death, indicating that the 
duration of follow-up can be used as a surrogate for survival. The 
significantly higher prostate cancer grade, stage and serum PSA in 
the black group can explain their shorter survival.
PSA testing to detect prostate cancer in asymptomatic men aged 
50 - 70 years has led to a dramatic stage migration in developed 
countries. Before its introduction, approximately 80% of men 
presented with incurable non-localised prostate cancer. Widespread 
PSA testing has resulted in at least 80% of men being diagnosed 
with potentially curable organ-confined cancer. PSA screening has 
reduced prostate cancer mortality by at least 20% in Europe.16 Owing 
to the risk of over-diagnosis and overtreatment and the costs of 
treatment, state-funded, population-wide PSA screening remains 
controversial. However, PSA testing of well-informed men at risk 
of prostate cancer produces a substantial stage migration towards 
early-stage, curable disease. Conversely, as our study demonstrates, 
where access to PSA screening of pre-symptomatic men is not readily 
available, most still present with locally advanced or metastatic, 
incurable prostate cancer.
Conclusions
During 1995 to 2005, black men in Western Cape Province presented 
with higher grade and stage prostate cancer and higher serum PSA 
levels than white or coloured men. Black men received potentially 
curative treatment less often and had a significantly shorter duration 
of follow-up than white or coloured men, probably owing to earlier 
death from prostate cancer. This demonstrates that in regions where 
PSA screening is not readily available and men with prostate cancer 
present because of cancer-related symptoms, the disease is locally 
advanced or metastatic (and therefore incurable) in most cases. 
Moreover, racial differences in stage at presentation and therapy 
indicate the need for greater prostate cancer awareness and education 
among patients and physicians. More widespread use of PSA for early 
detection in men at increased risk of prostate cancer and who are 
candidates for potentially curative therapy, is also supported.
The authors thank Mrs Mariëtte Pretorius, who maintained the prospective 
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clinical summaries and operation reports of patients.
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